Fig 3.

Kaplan-Meier estimates of overall survival by (A) age subgroup and (B) baseline patient characteristics. (*) Includes patients in the prespecified randomization strata of antecedent myelodysplastic syndrome (MDS) with prior hypomethylating agent (HMA) exposure as well as patients in other strata (eg, therapy-related acute myeloid leukemia [AML], antecedent chronic myelomonocytic leukemia [CMML]) who had previously received HMAs. Some patients received HMAs for therapy-related MDS, which then progressed to AML, and these patients may have been classified as having either therapy-related AML or antecedent MDS with prior HMA exposure. 7+3, standard-of-care cytarabine plus daunorubicin chemotherapy; CPX-351, dual-drug liposomal encapsulation of cytarabine and daunorubicin; FLT3, FMS-like tyrosine kinase 3; HR, hazard ratio; OS, overall survival.